欢迎来到艾兰博曼,请 登录 | 立即注册
查看: 1137|回复: 0

Oncogene:恶性前列腺癌生物标志物的发现有助于指导临床治疗

[复制链接]

1

听众

0

收听

45

积分

版主

Rank: 7Rank: 7Rank: 7

积分
45
发表于 2013-11-27 16:35:54 | 显示全部楼层 |阅读模式

                               
登录/注册后可看大图
2013年11月21日 英国科学家鉴定出能够区分恶性前列腺癌的特殊蛋白,未来可依据该蛋白表达情况确定针对不同病人治疗方法。相关报道发表在近期的Oncogene杂志上。
科学家发现相对健康组织,前列腺癌组织中有高水平的NAALADL2蛋白表达,该蛋白的高表达特性足以作为扩散到全身的恶性前列腺癌的标志。
科学家在两组病人中尝试用该蛋白做标记物诊断前列腺癌。更重要的是,该蛋白有可能确定恶性前列腺癌的病人,这些病人需要医生特别的重视,需要手术,化疗,放疗等多种疗法治疗。而低蛋白水平的前列腺癌患者更需要观察而不是治疗。
该文章的第一作者Hayley Whitaker博士称,该研究还是处于初级阶段,我们需要进一步进行临床试验确定该蛋白作为恶性前列腺癌的标记物的有效性。但是该研究是前列腺癌研究领域一个重要的发现,能够区分不同类型的前列腺癌对后期治疗有重要的指导意义。
英国前列腺癌专家Malcolm Mason博士称,作为前列腺癌临床医生,我一直希望有确定恶性前列腺癌的测试方法,我希望有一天该研究真正的能够用于指导临床。



                               
登录/注册后可看大图


N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype

N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2) is a member of the glutamate carboxypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1). Using immunohistochemistry (IHC), we have shown overexpression of NAALADL2 in colon and prostate tumours when compared with benign tissue. In prostate cancer, NAALADL2 expression was associated with stage and Grade, as well as circulating mRNA levels of the NAALADL2 gene. Overexpression of NAALADL2 was shown to predict poor survival following radical prostatectomy. In contrast to PSMA/NAALAD1, NAALADL2 was localized at the basal cell surface where it promotes adhesion to extracellular matrix proteins. Using stable knockdown and overexpression cell lines, we have demonstrated NAALADL2-dependent changes in cell migration, invasion and colony-forming potential. Expression arrays of the knockdown and overexpression cell lines have identified nine genes that co-expressed with NAALADL2, which included membrane proteins and genes known to be androgen regulated, including the prostate cancer biomarkers AGR2 and SPON2. Androgen regulation was confirmed in a number of these genes, although NAALADL2 itself was not found to be androgen regulated. NAALADL2 was also found to regulate levels of Ser133 phosphorylated C-AMP-binding protein (CREB), a master regulator of a number of cellular processes involved in cancer development and progression. In combination, these data suggest that changes in expression of NAALADL2 can impact upon a number of pro-oncogenic pathways and processes, making it a useful biomarker for both diagnosis and prognosis.
信息来源:生物谷



您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

© 2013 艾兰博曼 All Rights Reserved.
( 浙ICP备07020270号-8 )
 
快速回复 返回顶部 返回列表